Navigation Links
Study Confirms Efficacy of Innovative Therapies' Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
Date:12/5/2013

POMPANO BEACH, Fla., Dec. 5, 2013 /PRNewswire/ -- In the first randomized, controlled study to compare the efficacy of NPWT with and without simultaneous irrigation, researchers found that NPWT with or without irrigation reduced the wound size at a far greater rate than the control therapy. In addition, results showed NPWT with simultaneous irrigation further reduced the amount of bioburden compared to wounds treated with NPWT alone.

The study, recently published in the November-December issue of Wound Repair and Regeneration, also analyzed the effects of different irrigation solutions on wound healing and bioburden reduction. Normal saline and Polyhexanide biguanide, commonly known as the antimicrobial Prontosan®, were evaluated as irrigant solutions and both improved bioburden over NPWT alone. Interestingly, normal saline was found just as effective as using the antimicrobial, Prontosan.  

"Our preclinical research affirmed our hypothesis that irrigation therapy is both an effective tool for wound healing and reducing bioburden. What makes this data so exciting from a clinical perspective is that irrigation therapy showed such dramatic results in healthy pigs, which are highly resistant to infection. These results are likely understating the full healing potential of irrigation therapy for chronic wounds in patients with multiple comorbidities," said Kathryn Davis, PhD, Department of Plastic Surgery, University of Texas Southwestern Medical Center and the lead author of the study. "The results beg for more clinically focused research and we're looking forward to putting our methodology to the test in a clinical trial in the coming months."

For the study, researchers established a rigorous porcine methodology where full thickness excisional wounds were placed on six different pigs. Each wound was inoculated with approximately 500 colony-forming units of Pseudomonas aeruginosa (bioburden) and left to incubate for three days before treatment began, thus allowing the colonies to establish before applying the different therapy conditions. This technique provided a more rigorous assessment of bioburden reduction than applying the therapies immediately after inoculation. Wounds were then treated for 21 days of therapy with either the control (no therapy), NPWT alone or NPWT with simultaneous irrigation. Normal saline or Prontosan, at low or high flow rates, were used as the irrigation conditions. NPWT was administered using Innovative Therapies Inc.'s (ITI) Quantum™ NPWT system at -125 mm Hg of pressure. At day 21, NPWT and all irrigation conditions had wound areas that were 50 percent smaller than the control wound areas.

"We're extremely encouraged with the study results that demonstrate Quantum's ability to heal wounds faster and reduce bioburden," said Sandra Berriman, PhD, vice president, medical affairs, ITI. "We know that chronic conditions, such as non-healing wounds, are a tremendous burden on both the patient and the healthcare system. At ITI, we believe it's important to support research that will not only continue to establish best practices, but also suggest new science and evaluate the value of wound care technology. This research is part of an on-going series of scientific studies currently being conducted by ITI to demonstrate the clinical and economic benefits of Quantum."

ITI's Quantum is a prime example of wound care technology that is providing enhanced wound healing in an economically efficient model. Quantum is the first fully-featured device to offer NPWT with simultaneous irrigation to combine continuous healing for patients with a cost-efficient purchase model in which hospitals pay only for therapy hours used.

"More research needs to be done, but irrigation therapy combined with NPWT as a standard is likely where wound care treatment is headed," stated Davis. "The use of irrigation therapy could open up many different scenarios to allow administration of other therapeutic solutions and may become the new standard in the not so distant future."

About ITI
Innovative Therapies, Inc. (ITI) is a privately-held medical device company specializing in advanced wound care. Founded in 2005, ITI is headquartered in Florida and holds patents for Quantum™, Svedman™, and SVED™ devices; proprietary foam dressings; and advanced simultaneous irrigation technology. To learn more, visit ITImedical.com.


'/>"/>
SOURCE Innovative Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... 2016 , ... An April Gallup survey found rising health care costs to ... Sun Health Senior Living (SHSL) may not share those same worries thanks to ... for the year, while holding the line on increasing their contributions, including premiums, deductibles ...
(Date:5/26/2016)... BELLEVUE, Wash. (PRWEB) , ... May 26, 2016 ... ... a trusted provider of comprehensive treatment for eating disorders, is opening a brand ... facility will provide individuals ages 8-17 and their families with even more specialized ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian Mehling, ... The conference was held during May 5-6, 2016 in Chicago, IL, USA. Dr. ...
Breaking Medicine News(10 mins):